Coalition of Biology and Chemistry for Ameliorating Antimicrobial Drug Discovery

Dipesh Dhakal and Jae Kyung Sohng

Department of Life Science and Biochemical Engineering, Sun Moon University, Asan-si, South Korea, Department of BT-Convergent Pharmaceutical Engineering, Sun Moon University, Asan-si, South Korea

Keywords: antimicrobial drugs, biological engineering, synthetic biology, chemical synthesis methods, metabolic engineering

Natural products (NPs) are superior starting point for the major antimicrobials used in clinical trials (Newman and Cragg, 2012; Butler et al., 2014). Such antimicrobial NPs can be obtained from different microorganisms (Polpass and Jebakumar, 2013) and plants (Atanasov et al., 2015). They can be broadly classified as (i) native NPs, (ii) derivatives of NPs, or (iii) synthetic products based on structures of NPs (Demain and Sanchez, 2009). While NPs exhibit a wide range of pharmacophores and a high degree of stereochemistry (Harvey et al., 2015), novel NPs with better activities still need to be developed. Versatile biological knowledge based synthetic-biology approaches, system-biology guided metabolic engineering techniques, enzymatic modifications, and synthetic chemistry methods can be utilized to maximize the benefit of NPs from the source organism (Dhakal et al., 2015, 2016). Thus, the optimum application of NPs can only be improved with considerable effort based on precise screening, higher production, and desirable structural diversification (Dhakal and Sohng, 2015).

ENGINEERING OF BIOLOGICAL SYSTEMS

The antibacterial compounds can be produced by microorganisms to higher multicellular organisms as plants and animals from marine and terrestrial sources (Berdy, 2005; Hayashi et al., 2013). Fundamentally, a stable, well-behaved chassis (host cell) is essential for the production of desirable molecules at a significant level (Keasling, 2012). For native source like plants, the yield of target molecule is lower, that too comes through hectic separation among multitude of other structurally similar compounds (Chemler and Koffas, 2008). Hence, easily manipulable biological systems (production hosts) are attractive platforms for the large-scale production of major NPs. These biological systems can be programmed to produce chemicals of interest with higher precision and cost effectiveness (Stephanopoulos and Vallino, 1991). The synergistic implementation of synthetic biological tools and system biology assisted metabolic engineering approaches can be fundamental for harnessing maximum utility from the biological systems (Stephanopoulos et al., 2012; Nielsen et al., 2014). Synthetic biology deals more precisely with the design and construction of new biological systems (e.g., genetic control systems, metabolic pathways, cells) that do not exist in nature. Metabolic engineering approaches concentrate more on the development of methods and concepts for analysis of metabolic networks or pathways, typically for finding targets to re-engineer cell factories (Nielsen et al., 2014). Whilst engineered microorganisms are used to produce target compounds, synthetic biology, and metabolic engineering overlap at the level of metabolic pathway construction, enabling biocatalyst engineering, and maximizing cellular productivity (Nielsen and Moon, 2013).

Some NPs are not amenable for production at a significant level or cryptic in the native host, or the hosts are genetically intractable. “Genome mining” approach has enabled the computation of
mined genetic data and the connection to particular NPs, even if they are cryptic or produced in insignificant titers (Ziemert et al., 2016). Thus, native hosts, genetically tractable alternative hosts or suitable heterologous hosts, can be used as a platform for system-level metabolic engineering approaches (Luo et al., 2015; Dhakal et al., 2016). Some of the key foundations (Figure 1) are briefly summarized below.

Strain Development and Engineering
The design of a metabolic pathway needs to be well-supported with an appropriate host, because a suitable host is only able to manifest the computational design or recombined genetic circuit in the form of a product (Medema et al., 2011; Keasling, 2012). The classical strain engineering techniques of mutate and screen (Adrio and Demain, 2006) have advanced to such extent that we are now entering to an synthetic biology approaches for developing efficient native/heterologous hosts (Luo et al., 2015). Actinomycetes species as S. coelicolor M1152 (Gomez-Escribano and Bibb, 2011) and S. avermitilis SUKA (Komatsu et al., 2013) have been successfully employed for heterologous production of different antimicrobials. Recently, the heterologous expression systems have been extended in other organisms as Bacillus subtilis (Li et al., 2015), Escherichia coli (Ross et al., 2014), and Aspergillus niger (Anyagou and Mortensen, 2015). Various rapid, high throughput and automated multiplex genome engineering techniques are providing advanced avenues for making it feasible to generate compound specific superhosts (Nyerges et al., 2016; Wang et al., 2016). However, the major constraint is finding the appropriate host for particular NPs, due to host specific discrepancy in metabolism particularly in terms of flux balance between primary metabolites (precursors) and secondary metabolites (target molecules).

Metabolic Pathway Design and Engineering
The discrepancy of metabolism in host can be reconfigured by design of optimal pathways leading to production of natural-noninherent or non-natural-noninherent molecules. Further introduction of enzymes with superior catalytic activity or rationally engineered by domain swapping, mutagenesis etc. can establish a perfect metabolic pathway and overcome the problem of rate limiting cascades (Lee et al., 2012). These in silico optimizations of major metabolic pathways or ancillary precursor supply pathways have been instrumental in the efficient production different molecules with antimicrobial values (Medema et al., 2012). But, the major drawback for most efficient metabolic pathway designs and redesigns for particular host is prerequisite information of its genome and expression profiles.

Systematic Modulation of Metabolic Pathways
In absence of complete information of genome or expression levels as well, engineering of an appropriate host and metabolic circuit can be assisted by the systematic modulation of the pathways. The controlled tuning based on regulated expression from promoters (Alper et al., 2005; Zhang et al., 2010) or the ribosome binding site (RBS) (Salis et al., 2009) is most commonly used for this purpose. Vicinity engineering by protein fusion (Yu et al., 2015) or the use of scaffolds of DNA (Conrado et al., 2012), RNA (Delebecque et al., 2011), and protein (Dueber et al., 2009) provides an amenable platform for increasing the rate of enzyme catalysis. Meanwhile, the complete metabolic pathway can be reorganized by generating an artificial pathway for smooth flow over the metabolic nodes, previously identified as bottlenecks (Luo et al., 2015). This tweaking of metabolic pathway assists in transferring the complex metabolic pathways in native/heterologous producer strain and thereof cost-effective production (Galanie et al., 2015). However, these type of systematic modulation are not easy to design and implement. There is lack of universality in these approaches depending on the metabolic genuity of the host strain, which demands for numerous hits and trials, cost, and time.

RATIONAL CONTRIBUTION FROM SYNTHETIC CHEMISTRY
In case of un-culturable organisms or non-clonable pathways, total synthesis can be valid approach for accessing designed analogs of target NPs. Moreover, by combining the synthetic chemistry and biosynthetic approaches, the access to libraries of synthetically intractable analogs has been permitted (Goss et al., 2012). The methods for in situ cultivations in artificial iChip devices that mimic their natural environment enabled isolation of a new antibiotics teixobactin, without detectable resistance (Ling et al., 2015). The exploitation of "not-yet cultured" biodiversity by such approaches can lead to the discovery of more novel effective molecules (Kolter and van Wezel, 2016). The target based screening of NPs has been a popular technique for identifying effective NPs by phenotypic or genotypic assays (Wang et al., 2013; Lee et al., 2016). The exploration of new environmental settings including the study of human flora suggests a new direction in the isolation of previously unpredicted NPs (Zipperer et al., 2016). Thus the rational contribution of the synthetic chemistry to biology can therefore undoubtedly result in the expedient generation of libraries of novel compounds with better activities (Figure 1).

Pre-modification or Supplementation Approach
The chemical synthesis of some precursors or scaffolds can be used to generate novel analogs. Basically, these can be: (1) precursor directed biosynthesis (Harvey et al., 2012) or (2) mutasynthesis (Kennedy, 2008). Precursor directed biosynthesis utilizes natural flexibility of the biosynthetic pathway toward accepting the chemically synthesized precursor analogs (Harvey et al., 2012). In mutasynthesis approach, the native biosynthetic enzymes are modified and an unnatural chemically synthesized building block is introduced to the engineered system. The host strain is engineered to limit the competitive pathways by the inactivation/exchange/modification of key enzymes to yield the maximum production of the desired products (Kirschning et al., 2007; Koryakina et al., 2016). Versatile antimicrobial compound classes have been generated by
The biological engineering approaches (A) and chemical inputs through synthetic chemistry (B) can be applied to producer hosts (native or heterologous) or their products from those hosts. These biological engineering approaches and combinatorial chemical diversity can be integrated in modular form (C) for developing novel or effective drug molecules.

**FIGURE 1** | Graphical summary of the integrated approach for drug discovery and development. The biological engineering approaches (A) and chemical inputs through synthetic chemistry (B) can be applied to producer hosts (native or heterologous) or their products from those hosts. These biological engineering approaches and combinatorial chemical diversity can be integrated in modular form (C) for developing novel or effective drug molecules.
these approaches (Weissman, 2007; Kennedy, 2008). However, the stereo/regio-specificity of the biosynthetic enzymes limit the abundant diversity, which can be amended by making substantial change in domain architecture of key biosynthetic enzymes.

**Post-modification or Complementation Approach**

To combat the influence of biosynthetic enzyme over chemical scaffolds, direct intervention of synthetic chemistry has been adopted as: (1) chemical transformation or (2) chemoenzymatic biosynthesis. In the first approach, the biological product is processed through single/multiple chemical reaction and decorated with the desired chemical scaffold. In latter approach, the microbial product is processed through iterative modes of biosynthetic mechanism along with chemical reactions, thus multiplexing the parent compounds with novel functionalities and delivering chemical libraries as new leads (Yan et al., 2013; Kim et al., 2015). The diversified chemical scaffolds were synthetically prepared and recruited at different biosynthetic stages of antimycin (ATN) biosynthesis in *Streptomyces* sp. NRRL 2,288 to generate library of ∼380 ATN-like compounds(Yan et al., 2013). Thus, these combinations of synthetic chemistry and biosynthetic engineering can be very promising approaches for generating diversified classes of antimicrobial compounds (Winn et al., 2016).

**THE CROSS BORDER INTERACTOME SCHEMA**

The integration and interaction of synthetic chemistry with biological processes has definitely broadened the scope of the development of antimicrobial agents, such as:

**Nanomedicine**

The combination/conjugation of NPs with the chemically or biologically generated nanoparticles has proven to be very popular (Singh et al., 2016). Nanoparticles are used for targeted drug delivery (Sun et al., 2014), enhancing the biological activities (Gurunathan et al., 2014), or enhancing the bioavailability (Xie et al., 2011). The toxicity and safety of such metallic nanoparticles for the clinical use is not well-studied. However, antimicrobial peptides (AMPs) with potent antibacterial activity are taken as potential drug candidate for treatment of various bacterial infections(Meneguetti et al., 2016). The structurally nanoengineered antimicrobial peptide polymers (SNAPPs) inspired by the naturally occurring AMP, are the best example of a biological concept facilitating the development of chemical synthesis based super-drugs (Lam et al., 2016).

**Perturbation of Signaling Factors**

The pathogenic bacteria frequently release small molecules commonly called as virulence factors. The study of such virulence factor or other signaling molecules can assist in understanding bases of pathogenicity and designing inhibitor molecules (Anthouard and DiRita, 2015). These inhibitor molecules can be either derived from suitable strain or chemically synthesized to combat the growth of pathogenic bacteria. It has been observed that there is the elicitation of novel NPs by cross-talk of some signaling molecules with other microorganisms in a co-culture (Goers et al., 2014) or the fermentation with chemical inducers (Yamazaki et al., 2015). The major limitation in these approaches is that most of them are solely based on hits and trials, nevertheless these biological-biological or chemical-biological interactome have proven contribution in production of known molecules and even expression of various cryptic molecules (Bertrand et al., 2014; Pimentel-Elardo et al., 2015).

**FUTURE PERSPECTIVE**

The chemistry directed evolution in NPs discovery has provided diversified bioactive molecules or chemical modulators. But the traditional chemical processes are limited in diversity generated through “one-synthesis/one-scaffold” approach (Hong, 2011), whereas effective antimicrobial NPs demands remarkable structural complexity (Luo et al., 2015). Moreover such processes are expensive requiring multiple reagents, equipment etc., and often leads to production of hazardous chemicals (Jha et al., 2015). In case of microbial cell factories (native, engineered, or heterologous) the necessary titer, yield, and productivity for industrial application is on demand, but generally difficult to achieve (Porro et al., 2014). The major constraint is appropriate flux balance for diverting primary metabolites to target molecules. Hence revolutionizing the drug discovery and development process by integrating both biological and chemical techniques to complement each other is long overdue. The chemically optimized precursors/scaffolds can be processed through bio-engineered super-hosts to generate antimicrobial compounds in combination and permutation modes. Furthermore, studies on novel drug delivery methods utilizing integrated approach of biology and chemistry have potential to broaden the utility and efficacy of these antimicrobial molecules (Abed et al., 2015). In summary, this integrative modular approach (Figure 1) can provide repositories of antimicrobials for eradication of different infections.

**AUTHOR CONTRIBUTIONS**

DD and JS made substantial, direct and intellectual contribution to the work, and approved it for publication with full consent.

**ACKNOWLEDGMENTS**

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) (NRF-2014R1A2A2A01002875). DD is grateful to all the mentors of John Innes/Rudjer Bošković Summer Schools in Applied Molecular Microbiology, 2016 for their inspiration for preparing this manuscript.
REFERENCES

Abed, N., Said-Hassane, F., Zouhiri, F., Moguin, J., Nicolas, V., Desmaele, D., et al. (2015). An efficient system for intracellular delivery of beta-lactam antibiotics to overcome bacterial resistance. Science. Rep. 5:13350. doi: 10.1038/srep13350

Adrio, J. L., and Demain, A. L. (2006). Genetic improvement of processes yielding microbial products. FEMS Microbiol. Rev. 30, 187–214. doi: 10.1111/j.1574-6976.2005.00009.x

Alper, H., Fischer, C., Nevoigt, E., and Stephanopoulos, G. (2005). Tuning genetic control through synthetic engineering. Proc. Natl. Acad. Sci. U.S.A. 102, 12678–12683. doi: 10.1073/pnas.0504604102

Anthraud, R., and DiRita, V. I. (2015). Chemical biology applied to the study of bacterial pathogens. Infect. Immun. 83, 456–469. doi: 10.1128/IAI.00214-14

Anyago, D. C., and Mortensen, U. H. (2015). Heterologous production of fungal secondary metabolites in Aspergillus. Front. Microbiol. 6:77. doi: 10.3389/fmicb.2015.00077

Atanasov, A. G., Wallentaber, B., Pferschner-Wenzig, E. M., Linder, T., Wawrosch, C., Uhrin, P., et al. (2015). Discovery and resupply of pharmacologically active plant-derived natural products: a review. Biotechnol. Adv. 33, 1582–1614. doi: 10.1016/j.biotechadv.2015.08.001

Berdy, J. (2005). Bioactive microbial metabolites. J. Antibiot. 58, 1–26. doi: 10.1093/iaj/2005.1

Bertrand, S., Bohni, N., Schnee, S., Schumpp, O., Gindro, K., and Wolfender, J. L. (2016). Engineering of intracellular reactions with rationally designed RNA polymerase using a synthetic biology platform. Appl. Microbiol. Biotechnol. 100, 9917–9931. doi: 10.1007/s00253-016-7705-3

Harvey, A. L., Edrada-Ebel, R., and Quinn, R. J. (2015). The re-emergence of natural products for drug discovery in the genomics era. Nat. Rev. Drug Discov. 14, 111–129. doi: 10.1038/nrd4510

Harvey, C. J., Puglisi, J. D., Pande, V. S., Cane, D. E., and Khosla, C. (2012). Precursor directed biosynthesis of an orthogonally functionalized erythromycin analogue: selectivity in the ribosome macroside binding pocket. J. Am. Chem. Soc. 134, 12239–12265. doi: 10.1021/ja306882q

Kawabata, M., Aizawa, F., and Shimizu, M. I. (2013). Antimicrobial compounds from natural sources. Front. Microbiol. 4:195. doi: 10.3389/fmicb.2013.00195

Hong, J. (2011). Role of natural product diversity in chemical biology. Curr. Opin. Chem. Biol. 15, 350–354. doi: 10.1016/j.copbio.2011.03.004

Jha, A. K., Dhakal, D., Van, P. T. T., Pokhrel, A. R., Yamaguchi, T., Jung, H. J., et al. (2015). Structural modification of herbicidexin by substrate-flexible cytochrome P450 and glycosyltransferase. Appl. Microbiol. Biotechnol. 99, 3421–3431. doi: 10.1007/s00253-015-6431-6

Keasling, J. D. (2012). Synthetic biology and the development of tools for metabolite engineering. Metab. Eng. 14, 189–195. doi: 10.1016/j.ymben.2012.01.004

Kennedy, J. (2008). Mutametabolites, chemobiosynthesis, and back to semi-synthesis: combining synthetic chemistry and biosynthetic engineering for diversifying natural products. Nat. Prod. Rep. 25, 25–34. doi: 10.1038/nptr007678A

Kim, E., Moore, B. S., and Yoon, Y. J. (2015). Reinvestigating natural product combinatorial biosynthesis with synthetic biology. Nat. Chem. Biol. 11, 649–659. doi: 10.1038/nchembio.1893

Kirschning, A., Taft, F., and Knobloch, T. (2007). Total synthesis approaches to natural product derivatives based on the combination of synthetic synthesis and metabolic engineering. Org. Biomol. Chem. 5, 3245–3259. doi: 10.1039/b707954g

Koller, B., and van Wezel, G. P. (2016). Goodbye to brute force in antibiotic discovery? Nat. Microbiol. 1:1520. doi: 10.1038/nmicrobiol.2015.20

Komatsu, M., Komatsu, K., Koiwai, H., Yamada, Y., Kozone, I., Izumikawa, M., et al. (2013). Engineered Streptomyces avermitilis host for heterologous expression of biosynthetic gene cluster for secondary metabolites. ACS Synth. Biol. 2, 384–396. doi: 10.1021/sb3001003

Koryakina, I., Kasey, C., McArthur, J. B., Lowell, A. N., Chemler, J. A., et al. (2016). Inversion of extender unit selectivity in the erythromycin polyketide synthase by acyltransferase domain engineering. ACS Chem. Biol. 12, 114–123. doi: 10.1021/acschembio.6b00732

Lam, S. J., O’Brien-Simpson, N. M., Pantarat, N., Sulistio, A., Wong, E. H., Chen, Y. Y., et al. (2016). Combating multidrug-resistant Gram-negative bacteria with structurally nanoengineered antimicrobial peptide polymers. Nat. Microbiol. 1:16162. doi: 10.1038/nmicrobiol.2016.162

Lee, J. W., Na, D., Park, J. M., Lee, J., Choi, S., and Lee, S. Y. (2012). Synthetic engineering of microorganisms for natural and non-natural chemicals. Nat. Chem. Biol. 8, 536–546. doi: 10.1038/nchembio.970

Lee, S. H., Wang, H., Labrolbi, M., Koseoglu, S., Zack, P., Mayhood, T., et al. (2016). TarO-specific inhibitors of wall teichoic acid biosynthesis restores β-lactam efficacy against methicillin-resistant staphylococci. Sci. Transl. Med. 8, 329ra32. doi: 10.1126/scitranslmed.aad7364

Li, Y., Li, Z., Yamanaka, K., Xu, Y., Zhang, W., Vlamakis, H., et al. (2015). Directed natural product biosynthesis gene cluster capture and expression in the model bacterium Bacillus subtilis. Sci. Rep. 5:9383. doi: 10.1038/srep09383

Ling, L. L., Schneider, T., Peoples, A. J., Spoerri, A. L., Engels, I., Conlon, B. P., et al. (2015). A new antibiotic kills pathogens without detectable resistance. Nature 517, 455–459. doi: 10.1038/nature14098

Luo, Y., Li, B. Z., Liu, D., Zhang, L., Chen, Y., Jia, B., et al. (2015). Engineered biosynthesis of natural products in heterologous hosts. Chem. Soc. Rev. 44, 5265–5290. doi: 10.1039/c5cs00025d

Medema, M. H., Breitling, R., Bovenberg, R., and Takano, E. (2011). Exploiting plug-and-play synthetic biology for drug discovery and production in microorganisms. Nat. Rev. Microbiol. 9, 131–137. doi: 10.1038/nrmicro2478

Meneguetti, B. T., MacHado, L. D., Oshiro, K. G., Nogueira, M. L., Carvalho, C. M., and Franco, O. L. (2016). Antimicrobial peptides from fruits and their potential...
use as biotechnological tools- a review and outlook. Front. Microbiol. 7:2136. doi: 10.3389/fmicb.2016.02136

Newman, D. J., and Cragg, G. M. (2012). Natural products as sources of new drugs over the 30 years from 1981 to 2010. J. Nat. Prod. 75, 311–333. doi: 10.1021/np200906s

Nielsen, D. R., and Moon, T. S. (2013). From promise to practice, the role of synthetic biology in green chemistry. EMBO Rep. 14, 1034–1038. doi: 10.1038/embor.2013.178

Nielsen, J., Fussenegger, M., Keasling, J., Lee, S. Y., Liao, J. C., Prather, K., et al. (2015). Activity-independent discovery of secondary metabolites using chemical elicitation and cheminformatic inference. ACS Chem. Biol. 10, 2616–2623. doi: 10.1021/acschembio.5b00612

Polpass, A. J., and Jebakumar, S. R. D. (2013). Non-streptomycete actinomycetes Pimentel-Elardo, S. M., Sørensen, D., Ho, L., Ziko, M., Bueler, S. A., Lu, S., Newman, D. J., and Cragg, G. M. (2012). Natural products as sources of new chemicals elicitation and cheminformatic inference. Synthetic Biol. 10, 2616–2623. doi: 10.1021/acschembio.5b00612

Nielsen, J., Fussenegger, M., Keasling, J., Lee, S. Y., Liao, J. C., Prather, K., et al. (2015). Activity-independent discovery of secondary metabolites using chemical elicitation and cheminformatic inference. ACS Chem. Biol. 10, 2616–2623. doi: 10.1021/acschembio.5b00612

Polpass, A. J., and Jebakumar, S. R. D. (2013). Non-streptomycete actinomycetes nourish the current microbial antibiotic drug discovery. Front. Microbiol. 4:240. doi: 10.3389/fmicb.2013.00240

Porro, D., Branduardi, P., Sauer, M., and Mattanovich, D. (2014). Old obstacles and new horizons for microbial chemical production. Curr. Opin. Biotechnol. 30, 101–106. doi: 10.1016/j.copbio.2014.06.009

Ross, A. C., Gulland, L. E., Dorrestein, P. C., and Moore, B. S. (2014). Targeted capture and heterologous expression of the Pseudoalteromonas alterochromide gene cluster in Escherichia coli represents a promising natural product exploratory platform. ACS Synth. Biol. 4, 414–420. doi: 10.1021/acs.sibio.4b00280q

Salis, H. M., Mirsky, E. A., and Voigt, C. A. (2009). Automated design of synthetic ribosome binding sites to control protein expression. Nat. Biotechnol. 27, 946–950. doi: 10.1038/nbt.1568

Singh, P., Kim, Y. J., Wang, C., Mathiyalagan, R., El-Agamy Farh, M., and Yang, D. C. (2016). Biogenic silver and gold nanoparticles synthesized using red ginseng root extract, and their applications. Artif. Cells Nanomed. Biotechnol. 44, 811–816. doi: 10.3109/21691401.2015.1008514

Stephanopoulos, G. (2012). Synthetic biology and metabolic engineering. ACS Synth. Biol. 1, 514–525. doi: 10.1021/sb300094q

Stephanopoulos, G., and Vallino, J. J. (1991). Network rigidity and metabolic engineering in metabolite overproduction. Science 252, 1675–1681. doi: 10.1126/science.1904627

Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., and Xia, Y. (2014). Engineered nanoparticles for drug delivery in cancer therapy. Angew. Chem. Int. Ed. Engl. 53, 12320–12364. doi: 10.1002/anie.201403036

Wang, H., Gill, C. J., Lee, S. H., Mann, P., Zuck, P., Meredith, T. C., et al. (2013). Discovery of wall teichoic acid inhibitors as potential anti-MRSA β-lactam combination agents. Chem. Biol. 20, 272–284. doi: 10.1016/j.chembiol.2012.11.013

Wang, H., Ruska, M. L., and Qi, L. S. (2016). CRISPR/Cas9 in genome editing and beyond. Annu. Rev. Biochem. 85, 227–264. doi: 10.1146/annurev-biochem-060815-014607

Weissman, I. J. (2007). Mutasynthesis-uniting chemistry and genetics for drug discovery. Trends Biotechnol. 25, 139–142. doi: 10.1016/j.tibtech.2007.02.004

Winn, M., Fyans, J. K., Zhuo, Y., and Micklefield, J. (2016). Recent advances in engineering nonribosomal peptide assembly lines. Nat. Prod. Rep. 33, 317–347. doi: 10.1039/C5NP00099H

Xie, X., Tao, Q., Zou, Y., Zhang, F., Guo, M., Wang, Y., et al. (2011). PLGA nanoparticles improve the oral bioavailability of curcumin in rats: characterizations and mechanisms. J. Agric. Food Chem. 59, 9280–9289. doi: 10.1021/jf202135

Yamazaki, H., Rotinsulu, H., Narita, R., Takahashi, R., and Namikoshi, M. (2015). Induced Production of halogenated epidithiodiketopiperazines by a marine-derived Trichoderma cf. brevicompactum with sodium halides. J. Nat. Prod. 78, 2319–2321. doi: 10.1021/acs.jnatprod.5b00669

Yan, Y., Chen, J., Zhang, L., Zheng, Q., Han, Y., Zhang, H., et al. (2013). Multiplexing of combinatorial chemistry in antimycycin biosynthesis: expansion of molecular diversity and utility. Angew. Chem. Int. Ed. Engl. 52, 12308–12312. doi: 10.1002/anie.201305569

Yu, K., Liu, C., Kim, B. G., and Lee, D. Y. (2015). Synthetic fusion protein design and applications. Biotechnol. Adv. 33, 155–164. doi: 10.1016/j.biotechadv.2014.11.005

Zhang, H., Wang, Y., Wu, J., Skalina, K., and Pfeifer, B. A. (2010). Complete biosynthesis of erythromycin A and designed analogs using E. coli as a heterologous host. Chem. Biol. 17, 1232–1240. doi: 10.1016/j.chembiol.2010.09.013

Ziemert, N., Alanjary, M., and Weber, T. (2016). The evolution of genome mining in microbes—a review. Nat. Prod. Rep. 33, 988–1005. doi: 10.1039/C6NP00025H

Zipperer, A., Konnerth, M. C., Laux, C., Berscheid, A., Janek, D., Weidenmaier, C., et al. (2016). Human commensals producing a novel antibiotic impair pathogen colonization. Nature 535, 511–516. doi: 10.1038/nature18634

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Dhakal and Sohng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.